ArticleCancer cell2021
Tim-4
Open access · bronzeAbstract read
In one paragraph
Article in Cancer cell, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 123 papers.
0numbers the graph read from it
0cells of the map it votes in
123citing papers in PubMed
10.2field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
123 citing papers in PubMed, 165 citations in OpenAlex.
- ApolipoproteinEiScience · 2026Article
- Pathophysiological roles of monocytes and macrophages in cancer.Nature reviews. Immunology · 2026Review
- Ascites reprograms innate lymphoid immune cells in ovarian cancer by promoting ILC2 enrichment and dysfunctional NK-cell states.Journal for immunotherapy of cancer · 2026Article
- Loss of tumor suppressor NF2 mediates resistance to CAR T cell and anti-PD-1 therapy: Strategies to restore immunotherapy sensitivity.Med (New York, N.Y.) · 2026Article
- CD300ld on pathologically activated neutrophils promotes tumor immune suppression by binding phosphatidylserine on CD8Nature cancer · 2026Article
- The cell with many faces: lung macrophage plasticity and function in response to environmental and pathogenic insults.Physiological reviews · 2026Review
- Phosphatidylserine exposure and cancer immune evasion.Cell research · 2026Article
- Heterogeneity of macrophages in PD-1/PD-L1 inhibitor therapy: a single-cell perspective.Cellular & molecular biology letters · 2026Review
- Kupffer cell calibration of T cell responses via VSIG4-CD5 interaction promotes tumor evasion.Nature immunology · 2026Article
- Combination Immunotherapy as a Promising Strategy to Overcome Immunotherapy Resistance: From Emergence to Next-Generation Approaches.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Review
- IL10R Inhibition Induces Neutrophil Tumoricidal Activity.Cancer immunology research · 2026Article
- Article
- Development and validation of nomograms integrating electrolyte, nutritional, and inflammatory indicators to predict survival in advanced esophageal cancer undergoing immunotherapy or radioimmunotherapy.Journal of thoracic disease · 2026Article
- Lipid metabolism as a central driver of immune remodeling and therapeutic vulnerability in metastatic colorectal cancer.Lipids in health and disease · 2026Review
- Therapy-induced remodeling of the tumor immune microenvironment: Mechanistic insights and implications for immunotherapy.Chinese medical journal · 2026Review
- Infiltration of TIM4-positive intratumoral macrophages serves as an adverse prognostic factor in breast cancer.Breast cancer (Tokyo, Japan) · 2026Article
- RT-ICI therapy induces a distal immunometabolic axis that shapes systemic macrophage polarization and enhances local T cell immunity.Cell communication and signaling : CCS · 2026Article
- Pleural cavity macrophages promote lung tumor establishment through tissue invasion.Protein & cell · 2026Article
- Macrophage states and immunometabolic adaptation in peritoneal metastases from colorectal cancer.Frontiers in immunology · 2026Review
- Article
63 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
41 authors at 5 institutions in 1 country.
Andrew ChowLudwig Collaborative and Swim Across America Laboratory, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Weill Cornell Medical College, New York, NY, USA.
Sara SchadWeill Cornell Medical College, New York, NY, USA.
Michael D GreenDepartment of Radiation Oncology, University of Michigan Rogel Cancer Center and Veterans Affairs Ann Arbor Healthcare System, MI, USA.
Matthew D HellmannDepartment of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Weill Cornell Medical College, New York, NY, USA; Parker Institute for Cancer Immunotherapy, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Viola AllajDepartment of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Nicholas CegliaDepartment of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Giulia ZagoImmunology Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Nisargbhai S ShahDepartment of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Sai Kiran SharmaDepartment of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Marissa MattarAntitumor Assessment Core Facility, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Joseph ChanDepartment of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Hira RizviDepartment of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Hong ZhongLudwig Collaborative and Swim Across America Laboratory, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Cailian LiuLudwig Collaborative and Swim Across America Laboratory, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Yonina BykovLudwig Collaborative and Swim Across America Laboratory, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Dmitriy ZamarinLudwig Collaborative and Swim Across America Laboratory, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Weill Cornell Medical College, New York, NY, USA.
Hongyu ShiDepartment of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Sadna BudhuLudwig Collaborative and Swim Across America Laboratory, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Corrin WohlhieterWeill Cornell Medical College, New York, NY, USA.
Fathema UddinDepartment of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Aditi GuptaLudwig Collaborative and Swim Across America Laboratory, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Inna KhodosAntitumor Assessment Core Facility, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Jessica J WaningerDepartment of Medical Education, University of Michigan School of Medicine, Ann Arbor, MI, USA.
Angel QinDepartment of Internal Medicine, University of Michigan School of Medicine, Ann Arbor, MI, USA.
Geoffrey J MarkowitzDepartment of Cardiothoracic Surgery, Weill Cornell Medicine, New York, NY, USA.
Vivek MittalDepartment of Cardiothoracic Surgery, Weill Cornell Medicine, New York, NY, USA.
Vinod BalachandranParker Institute for Cancer Immunotherapy, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Hepatopancreatobiliary Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Jennifer N DurhamSidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Dung T LeSidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Weiping ZouDepartments of Surgery and Pathology, Center of Excellence for Cancer Immunology and Immunotherapy, University of Michigan Rogel Cancer Center, University of Michigan School of Medicine, Ann Arbor, MI, USA.
Sohrab P ShahDepartment of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Andrew McPhersonDepartment of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Katherine PanageasDepartment of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Jason S LewisWeill Cornell Medical College, New York, NY, USA; Molecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Justin S A PerryImmunology Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Elisa de StanchinaAntitumor Assessment Core Facility, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Triparna SenDepartment of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Weill Cornell Medical College, New York, NY, USA; Molecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
John T PoirierPerlmutter Cancer Center, New York University Langone Health, New York, NY, USA.
Jedd D WolchokLudwig Collaborative and Swim Across America Laboratory, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Weill Cornell Medical College, New York, NY, USA; Parker Institute for Cancer Immunotherapy, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Immunology Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Charles M RudinDepartment of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Weill Cornell Medical College, New York, NY, USA; Molecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA. Electronic address: rudinc@mskcc.org.
Taha MerghoubLudwig Collaborative and Swim Across America Laboratory, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Weill Cornell Medical College, New York, NY, USA; Parker Institute for Cancer Immunotherapy, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Immunology Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA. Electronic address: merghout@mskcc.org.
Memorial Sloan Kettering Cancer Center · USCornell University · USUniversity of Michigan · USJohns Hopkins University · USNYU Langone Health · US
Funding
X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Nicholas D Socci · 1985 to 2026
$347.4MMICHIGAN MEDICAL SCIENTIST TRAINING PROGRAMT32GM007863 · NIGMS · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI COLLINS, KATHLEEN L. · 1985 to 2024
$38.3MThe Role of Focal Oncogene Amplifications in Lung CancerP01CA129243 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI Marc Ladanyi · 2007 to 2026
$31.2MInvestigational Cancer Therapeutics Training Program (ICTTP)T32CA009207 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Omar Abdel-Wahab, Alexander Drilon · 1985 to 2026
$13.7MCoordinating center for the NCI small cell lung cancer research consortiumU24CA213274 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI Lauren Averett Byers, JOHN D. MINNA · 2017 to 2026
$12.9MLeveraging Pb-203/212 for the Theranostic Imaging and Therapy of Prostate CancerR35CA232130 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI LEWIS, JASON S. · 2019 to 2025
$8.2MIMMUNIZATION AGAINST MELANOMA DIFFERENTIATION ANTIGENSR01CA056821 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI WOLCHOK, JEDD D. · 1992 to 2020
$5.7MDeterminants of acquired resistance in small cell lung cancerR01CA197936 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI RUDIN, CHARLES M. · 2016 to 2020
$3.1MIdentification and validation of synthetic lethality in KRAS mutant lung adenocarcinoma patient derived xenograftsU01CA199215 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI POIRIER, JOHN THOMAS, RUDIN, CHARLES M. · 2015 to 2019
$2.7MAssessment of Tim-4+ Pleural Macrophages as Negative Regulators of Anti-Tumor T Cell Immunity in Lung CancerK08CA248723 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI CHOW, ANDREW · 2020 to 2022
$602kNCI NIH HHS K08 CA248723NCI NIH HHS P01 CA129243NCI NIH HHS P30 CA008748NCI NIH HHS R01 CA056821NCI NIH HHS R01 CA197936NCI NIH HHS R35 CA232130NCI NIH HHS T32 CA009207NCI NIH HHS U01 CA199215NCI NIH HHS U24 CA213274NIGMS NIH HHS T32 GM007863
Abstract
Immune checkpoint blockade (ICB) has been a remarkable clinical advance for cancer; however, the majority of patients do not respond to ICB therapy. We show that metastatic disease in the pleural and peritoneal cavities is associated with poor clinical outcomes after ICB therapy. Cavity-resident macrophages express high levels of Tim-4, a receptor for phosphatidylserine (PS), and this is associated with reduced numbers of CD8
Indexed as
Gene Expression Regulation, NeoplasticTumor MicroenvironmentAnimalsApoptosisCD8-Positive T-LymphocytesCell ProliferationColonic NeoplasmsFemaleHumansMacrophagesMembrane ProteinsMiceMice, Inbred BALB CMice, Inbred C57BLPrognosisRetrospective StudiesMembrane ProteinsTIM-4 protein, mouseTIMD4 protein, humancavity-resident macrophagesCD8(+) T cellsimmune checkpoint blockadeimmunotherapyperitoneal macrophagesphosphatidylserinepleural macrophagesscRNA-seqsequestrationTim-4
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.